Bid price | 60.00 | Open price | 60.25 |
---|---|---|---|
Ask price | 65.00 | Prev close | 62.50 |
High price | 0.00 | Spread | 7.69% |
Low price | 0.00 | Volume | 0 |
Register now for FREE live Redx Pharma share prices, Redx Pharma stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Redx Pharma Level 2 Data, indepth research tools and investor commentary for Redx Pharma (REDX) and other London Stock Exchange equities.
Register now for FREE Redx Pharma share price charts
Name | Redx Pharma | Epic | REDX |
---|---|---|---|
Sector | n/a | ISIN | GB00BSNB6S51 |
Activites | n/a | Index | n/a |
Dec.Date | Type | Director | Pos | No. of Shares |
---|---|---|---|---|
18/04/2024 | BUY | Lisa Anson | CEO | 74,500 |
18/04/2024 | BUY | Lisa Anson | CEO | 115,000 |
12/04/2024 | BUY | Lisa Anson | CEO | 399,000 |
23/12/2020 | BUY | Lisa Anson | CEO | 39,998 |
21/12/2020 | PLAC | Iain Ross | RES | 35,130 |
Cancer and fibrosis focused Redx Pharma said it would raise up to £27.7 million from a share issue to fund its clinical programmes and pre-clinical research. News shares in the company were being offered at 56p each, a 2.6% discount to Redx's closing price on Tuesday. The offer included a £25.5...
RNS Number : 2030H Redx Pharma plc 02 December 2020 Redx Pharma plc ("Redx" or "the Company") New Grant of Options Alderley Park, 2...
RNS Number : 2142H Redx Pharma plc 02 December 2020 THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,...
More Redx Pharma Company News >>
Register now for FREE Redx Pharma company news
Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in two main areas, cancer and infectious disease. The company's work has been endorsed by partnerships with global...
Register now for FREE Redx Pharma share price discussions